All companies
Visit website
Quadrant Biosciences
OperatingQuadrant Biosciences Inc
Founded 2015
Improving the lives of children by diagnosing autism earlier
Post-money valuation ⓘ
$266.9M
As of Aug 2020 · from Quadrant Biosciences Inc Reg A 1 · pre-money + amount raised, not a traded price
Total raised
$1,308,719
Across 2 rounds since 2020
Latest share price
$3.00
Quadrant Biosciences Inc Reg A 1 offering price
Financials
FY2018–FY2022 · from SEC filings · hover any figure for its source$116K
−$6.9M
2018
$414K
−$7.3M
2019
$11.8M
$1.7M
2020
$60.5M
$12.2M
2021
$36.4M
−$2.4M
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2018
FY2019
FY2020
FY2021
FY2022
Income statement
Revenue
$115,778
$413,811
$11,801,123
$60,519,179
$36,395,155
Cost of goods sold
$192,281
$426,512
$8,609,760
$33,466,238
$14,340,093
Gross margin
-66%
-3%
27%
45%
61%
Net income
-$6,943,093
-$7,296,264
$1,732,052
$12,247,807
-$2,444,757
Taxes paid
-$237,516
$0
$0
$159,290
$57,859
Balance sheet
Cash
$4,945,726
$1,289,474
$9,743,455
$8,116,233
$13,882,387
Accounts receivable
$24,077
$12,653
$1,354,350
$13,651,979
$1,411,933
Total assets
$9,091,991
$8,672,233
$25,139,833
$38,227,705
$36,301,229
Short-term debt
$650,959
$736,722
$10,985,782
$7,393,024
$8,833,130
Long-term debt
$5,398,139
$5,349,064
$5,707,571
$7,016,522
$1,900,436
Total liabilities
$5,947,496
$6,085,786
$16,693,353
$14,409,546
$10,733,566
Other
Headcount
42
42
42
126
126
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$266.9M
post-money
Quadrant Biosciences Inc Reg A 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $360.1K / $1.1M
Raised $948.7K / $15MPost-money $266.9M
Reg CF annual-report compliance
Possibly delinquent
Filed 3 of 6 annual reports (FY2020–FY2025)
Missing: 2023, 2024, 2025
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 27 filings on EDGARSource: ManualCIK 0001651239Share price $3.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.